Skip to main content

Table 3 Percentage change from baseline in lipid variables at 4 weeks (ITT population)

From: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Variable

Least-squares mean percentage change from baseline to 4 weeks

Difference (95% CI)

p-value

Rosuvastatin 10 mg (n = 232)

Atorvastatin 10 mg (n = 231)

LDL-C

-47.6

-38.5a

-9.1 (-11.4, -6.7)

< 0.0001

TC

-33.6

-27.9

-5.7 (-7.4, -4.0)

< 0.0001

HDL-C

4.4

2.6

1.8 (-0.5, 4.0)

NS

TG

-19.2

-15.5

-3.7 (-9.5, 2.2)

NS

Non-HDL-C

-42.6

-35.0

-7.6 (-9.6, -5.7)

< 0.0001

LDL-C/HDL-C ratio

-49.3

-39.5

-9.8 (-12.2, -7.4)

< 0.0001

Non-HDL-C/HDL-C ratio

-44.4

-35.9

-8.5 (-10.8, -6.2)

< 0.0001

TC/HDL-C ratio

-35.8

-29.0

-6.7 (-8.7, -4.8)

< 0.0001

Apo B

-42.9

-35.3

-7.6 (-9.7, -5.6)

< 0.0001

Apo A-I

2.6

0.8

1.8 (0, 3.5)

0.05

Apo B/apo A-I ratio

-43.9

-35.4

-8.5 (-10.6, -6.4)

< 0.0001

  1. ITT: Intention to treat, CI: Confidence interval, LDL-C: Low-density lipoprotein cholesterol, TC: Total cholesterol, HDL-C: High-density lipoprotein cholesterol, TG: Triglycerides, Apo: Apolipoprotein, NS: Not statistically significant
  2. an = 232